Select a Seminar
Session 1Session 2Session 3Session 4

The Cole Eye Institute Imaging Summit took place on July 19, 2018 prior to the American Society of Retina Specialists (ASRS).

The is a CME symposium focusing on new advances in OCT imaging with hands-on imaging sessions. Attendees will be able to discuss current topics in tomography and imaging with a faculty of distinguished peers. Ocular imaging technology is an area of intense innovation with every year bringing better and more options to the clinic. Outcomes in vision care are best when ophthalmologists, retina specialists, and other eye care health practicioners remain informed of the latest ocular imaging capabilities. Following this course, learners will be able to better select appropriate diagnostic testing and better interpret those tests to improve patient care. Additionally, learners will be made aware of new and exciting modalities of ophthalmic imaging that can be implemented into their clinical practice.

Session Topics

  • OCT Angiography: Swept Source vs Spectral Domain – Peter K. Kaiser, MD
  • Clinical Applications of OCT Angiography – Nadia K. Waheed, MD
  • Advanced Retinal Imaging Supports an In-series Organization of the Retinal Capillary Plexus – David Sarraf, MD
  • OCT Angiography in Inflammatory Eye Disease: Do We Need It? – Sumit Sharma, MD
  • Panel Discussion: Where Do I Use OCT-A in My Clinical Practice? – Sunil K. Srivastava, MD

NEW AND EMERGING TRENDS IN OCT ANGIOGRAPHY

  • New and Emerging Trends In OCT Angiography

    Drs. Kaiser, Waheed, Sarraf, Sharma & Srivastava
Take The Course Post-Test & Evaluation
Target Audience

The Cole Eye Institute Imaging Summit is for comprehensive ophthalmologists, retina specialists, retina fellows and healthcare providers who are interested in applying the most current, cutting-edge OCT imaging knowledge, including emerging techniques for imaging and treating retinal diseases.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
• Use imaging to identify ocular pathologies
• Accurately interpret images
• Document and archive ocular findings efficiently
• Educate patients using images
• Implement new imaging technologies in practice

Method of Participation

Statements of credit will be awarded based on the participant’s attendance. A statement of credit will be available upon completion of an online evaluation/claimed credit form available at jgoldman@akhcme.com.

Please claim your credit by December 27, 2019.

If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

Disclaimer


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by an educational grant from: Carl ZEISS Meditec, Inc., Genentech, Inc. and Regeneron Pharmaceuticals, Inc.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Faculty Disclosures

Justis Ehlers, MD

  • Consultant: Aerpio; Alcon, a Novartis division; Alimera; Carl ZEISS Meditec, Inc.; Genentech, Inc.; Leica; Novartis; Roche; Santen; Thrombogenics
  • Contracted Research: Aerpio; Alcon, a Novartis division; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.

Peter K. Kaiser, MD

  • Consultant: Aerie Pharmaceuticals; Aerpio; Alcon; Allegro; Allergan; Bausch + Lomb; Bayer; Biogen Idec; Boehringer Ingelheim; Galecto Biotech AB; Hospira; jCyte; Kanghong Pharmaceutical; Kodiak Sciences; Novartis; Ohr Pharmaceutical; Omeros; Regeneron Pharmaceuticals, Inc.; Retinal Sciences; Santen; SciFluor; Shire; Spark Therapeutic; Thrombogenics; Valeant Pharmaceuticals International, Inc

Daniel F. Martin, MD

  • Nothing to disclose

Anant Madabhushi, PhD

  • Nothing to discloseYasha S. Modi, MD
  • Consulting: Alimera; Allergan; Genentech, Inc.Prithvi Mruthyunjaya, MD, MHS
  • Consulting: Castle Biosciences; Optos

SriniVas R. Sadda, MD

  • Consulting: 4D Molecular Therapeutics; Allergan; Carl ZEISS Meditec, Inc.; CenterVue; Genentech, Inc; Heidelberg; Iconic Therapeutics; Nightstar; Novartis; Optos plc; Thrombogenics
  • Contracted Research: Allergan; Carl ZEISS Meditec, Inc.; Genentech, Inc.; Optos plc
  • Research Instruments: Carl ZEISS Meditec, Inc.; CenterVue Inc.; Heidelberg; Nidek; Topcon Corporation

David Sarraf, MD

  • Consulting: Amgen; Bayer; Genentech, Inc.; Novartis; Optovue
  • Contracted Research: Genentech, Inc.; Heidelberg; Optovue; Regeneron Pharmaceuticals, Inc.
  • Speaker Bureau: Bayer; Optovue

Sumit Sharma, MD

  • Consulting: Allergan; Mallinckrodt Pharmaceuticals

Rishi P. Singh, MD

  • Consultant: Alcon, a Novartis division; Carl ZEISS Meditec, Inc.; Genentech, Inc.; Optos plc; Regeneron Pharmaceuticals, Inc.
  • Contracted Research: Apellis Pharmaceuticals; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.

Sunil K. Srivastava, MD

  • Consultant: Bausch + Lomb; Clearside BIO; Gilead Sciences, Inc.; Optos plc; pSivida Corp.; Regeneron Pharmaceuticals, Inc.; Santen
  • Contracted Research: Allergan; Bausch + Lomb; Regeneron Pharmaceuticals, Inc.; Santen

Nadia K. Waheed, MD

  • Consultant: Carl ZEISS Meditec, Inc.; Genentech; Heidelberg; Nidek; Novartis; Optovue; Regeneron; Topcon Corporation
  • Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose
Take The Course Post-Test & Evaluation
X

PRE-QUESTIONS

Please answer the following pre-questions before moving on to the session presentations.

First Name*
Last Name*
Email*

Swept source is better than spectral domain OCT for OCTA because

*
Worse signal to noise requires image averaging for better images
Uses Fourier transformation which is more precise than algorithm used in swept source
Deeper penetration allows better imaging of the choroid
Faster scan speeds

OCT angiography

*
Does not have the ability to be depth resolved
Uses flow of blood through vessels as intrinsic contrast
Can be used to detect speed of flow
Can be used to measure total retinal blood flow

OCTA is useful to monitor which of the all of the following changes in eyes with uveitis EXCEPT:

*
Nonperfusion
Leakage
CNV
Choroidal Lesions